A neuron


About us

Our mission is to deploy our platform technology across a pipeline of  drugs, targeting  largely unmet medical conditions in which RAS is implicated.   

We and our collaborators are global leaders in the chemistry and biology of RAS deactivation and how this strategy can treat CNS related disorders including trauma and neurodegenerative diseases. Our first indication will be neuropathic pain in spinal cord injury (SCI), a condition which affects 50% of SCI patients, for whom current treatments, including addictive opioids, are significantly inadequate.   

As we progress through clinical trials in SCI neuropathic pain, we will extend our indications to address other sources of neuropathic pain (e.g., chemotherapy, diabetes) and neuro-degenerative disease, such as multiple sclerosis and Parkinsons, in which RAS contributes to progression, pain and lack of mobility.  

We and our collaborators are global leaders in the chemistry and biology of RAS deactivation


Our team is devoted to pursue Neuro Vigor's objective of neutralizing RAS.

Dr. Riyi Shi - MD, PhD

Purdue University neuroscientist. Endowed Professor of Applied Neuroscience and Director of the Center for Paralysis Research, a pioneer in toxic aldehydes and their reduction.

Dr. Nicholas Race - MD, PhD

Neuroscientist, biomedical engineer, and physical medicine and rehabilitation (PM&R) physician at the University of Pittsburgh with preclinical and clinical expertise in central nervous system injuries, neurodegeneration, and neuropathic pain.

Mark Van Fleet

Entrepreneur, and former senior executive at the U.S. Chamber of Commerce, where he led teams creating new international initiatives. Founded and managed two start-up consulting firms and Purdue’s Global Business Engagement program.

David Giddings

C-level life sciences career including positions as President & COO of Boehringer Mannheim Corp and Chairman, President, and CEO of Diametrics Medical. An independent corporate adviser for early and development stage Biotech, MedTech, and Analytics companies.


Dr. Philip Burcham - PhD

Associate Professor, Pharmacology and Toxicology, University of Western Australia, is one of the world’s foremost reactive aldehyde researchers and toxicologists. Ongoing efforts in close partnership with Dr. Piggott and NVT to develop next-generation RAS scavengers.

Dr. Matthew Piggott - PhD

Associate Professor, School of Molecular Sciences, University of Western Australia, is a synthetic chemist with deep expertise in design and synthesis of novel compounds for medical use.

Dr. Brad Lang - PhD

Translational Neuroscientist with broad expertise in drug discovery/development for neurological indications.  Listed inventor on >10 small and large molecule patents including NVG-291 composition of matter (P1 clinical trials).  Scientific Founder of Nervgen, VP of Research of Convelo Therapeutics.

Dr. Palaniappan Kulanthaivel - PhD

Director of drug development. 25+ years of pharmaceutical discovery and development experience, including neurological indications, as a former executive and pharmacology expert with Eli Lilly.

Dr. Ian Mills - MD, PhD

15+ years in a variety of clinical and development leadership roles related to drug discovery and development including commercialization of our pathfinder drug.